Acute Fatty Liver of Pregnancy

Acute Fatty Liver of Pregnancy (AFLP): A Comprehensive Clinical Guide

Acute Fatty Liver of Pregnancy (AFLP) is a rare, life-threatening obstetric emergency characterized by microvesicular fatty infiltration of hepatocytes. Occurring typically in the third trimester or the early postpartum period, this condition represents a dramatic failure of hepatic function that can rapidly progress to multi-organ system failure. Due to its rarity and non-specific presentation, AFLP requires a high index of clinical suspicion, rapid diagnostic evaluation, and immediate multidisciplinary intervention.

1. Clinical Definition and Etiology

Definition

AFLP is a disorder of fatty acid oxidation occurring during pregnancy. It is clinically defined by the rapid onset of hepatic dysfunction, which may culminate in liver failure, coagulopathy, hypoglycemia, and encephalopathy. If untreated, maternal and fetal mortality rates are significantly high.

Etiology and Pathophysiology

The primary mechanism underlying AFLP is a defect in mitochondrial fatty acid beta-oxidation within the fetus, which secondarily impacts the mother.

• The LCHAD Connection: The most common genetic trigger is a deficiency in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) in the fetus.
• Mechanism: When the fetus lacks the enzymes necessary to metabolize long-chain fatty acids, these toxic intermediates accumulate and cross the placenta into the maternal circulation.
• Hepatic Damage: The maternal liver is unable to process these elevated levels of circulating long-chain fatty acids, leading to their accumulation within maternal hepatocytes. This results in microvesicular steatosis (the hallmark of AFLP), which impairs mitochondrial function, decreases ATP production, and leads to hepatocellular necrosis and systemic metabolic failure.

2. Clinical Staging and Grading

While there is no universally accepted "staging system" in the same vein as cancer, clinicians utilize the Swansea Criteria to grade the severity and confirm the diagnosis of AFLP.

The Swansea Criteria (Diagnostic Thresholds)

A diagnosis is highly suggested if six or more of the following clinical/laboratory criteria are met:

3. Standard Presentation and Clinical Indications

Clinical Presentation

The onset is often insidious, progressing to fulminant liver failure over several days to weeks.

• Prodromal Phase (1–2 weeks): Malaise, anorexia, nausea, vomiting, and epigastric/right upper quadrant abdominal pain.
• Acute Phase: Jaundice, progressive confusion (encephalopathy), and signs of fluid overload (ascites).
• Late Complications: Gastrointestinal bleeding (due to coagulopathy), renal failure (hepatorenal syndrome), and sepsis.

Key Diagnostic Tests

1. Laboratory Panel: Complete Blood Count (CBC) to monitor platelets and leukocytes; Liver Function Tests (LFTs) for elevated transaminases; Coagulation profile (PT/INR/PTT); Serum ammonia and glucose levels.
2. Imaging: Abdominal Ultrasound is the first-line modality to visualize "bright liver" (steatosis) or ascites. Computed Tomography (CT) or MRI may be used if ultrasound is inconclusive, though they are rarely required in an acute setting.
3. Liver Biopsy: Historically the "gold standard," it is now rarely performed due to the high risk of hemorrhage in coagulopathic patients. It is reserved for diagnostic uncertainty.

4. Differential Diagnosis

AFLP must be distinguished from other pregnancy-associated liver diseases. The table below outlines the key differences:

5. Risks, Side Effects, and Contraindications

Maternal Risks

• Disseminated Intravascular Coagulation (DIC): Secondary to liver synthetic failure.
• Acute Kidney Injury (AKI): Often requiring temporary renal replacement therapy.
• Hepatorenal Syndrome: Poor prognosis without rapid delivery.
• Postpartum Hemorrhage: Due to the inability to synthesize clotting factors.

Fetal Risks

• Hypoxia: Secondary to maternal metabolic instability.
• Preterm Delivery: Often necessitated by the need to stabilize the mother.
• Genetic Risk: If the fetus has LCHAD deficiency, they face long-term metabolic health challenges post-delivery.

Management Contraindications

• Delaying Delivery: The only definitive treatment for AFLP is the immediate delivery of the fetus, regardless of gestational age. Delaying to achieve fetal lung maturity is contraindicated and dangerous.
• Elective Induction: In severe cases, emergency Cesarean section is often prioritized over induction if the mother is hemodynamically unstable.

6. Long-Term Prognosis

With early diagnosis and delivery, maternal survival rates have improved dramatically to >90%. Recovery of liver function typically occurs within a few weeks postpartum.

• Long-term Liver Health: Most survivors experience full recovery of hepatic function without chronic liver disease.
• Recurrence: Recurrence in subsequent pregnancies is rare but possible. Genetic counseling is advised to determine if the mother or father carries a mutation in the HADHA gene (the gene associated with LCHAD deficiency).

7. Frequently Asked Questions (FAQ)

1. Is AFLP the same as HELLP syndrome?

No. While both occur in the third trimester, AFLP is a fatty acid oxidation disorder causing liver failure, whereas HELLP is a variant of pre-eclampsia characterized by hemolysis and platelet consumption.

2. Does the liver recover after pregnancy?

Yes, in the vast majority of cases, the liver regenerates and functions normally within 2 to 4 weeks postpartum.

3. What is the most important treatment?

Immediate delivery of the fetus. The maternal liver disease will not stabilize until the fetus (the source of the toxic fatty acids) is delivered.

4. Is a liver biopsy necessary for diagnosis?

No. Because of the risk of bleeding due to low clotting factors, biopsies are rarely performed. Clinical criteria like the Swansea criteria are preferred.

5. Can I have a vaginal birth if I have AFLP?

Vaginal delivery is preferred if the patient is stable. However, if the mother is unstable or there is fetal distress, an emergency Cesarean section is required.

6. Is AFLP hereditary?

The condition is linked to fetal LCHAD deficiency, which is an autosomal recessive disorder. If both parents are carriers, there is a 25% chance of the fetus having the condition in each pregnancy.

7. What are the early warning signs?

Persistent nausea and vomiting that is more severe than typical "morning sickness," combined with severe epigastric pain and jaundice.

8. Does AFLP always lead to liver failure?

If untreated, yes. Early intervention can stop the progression before full-blown hepatic coma or multi-organ failure occurs.

9. What is the role of the ICU in AFLP?

Patients with AFLP require intensive care monitoring for hypoglycemia, coagulopathy, and potential renal failure. Many require blood product support (FFP, cryoprecipitate) and glucose infusions.

10. Can AFLP occur after birth?

Yes, symptoms can occasionally present or persist in the early postpartum period, requiring continued monitoring.

Conclusion

Acute Fatty Liver of Pregnancy is a sentinel event in obstetric medicine. While the pathophysiology is rooted in rare genetic metabolic defects, the clinical manifestation is a systemic crisis. The "gold standard" of care remains high-index clinical suspicion, prompt recognition via the Swansea criteria, and the decisive move toward delivery. As a specialist, it is imperative to coordinate care between obstetrics, hepatology, and critical care teams to ensure the survival of both mother and neonate.

Disclaimer: This guide is intended for medical education and information purposes only. It does not replace the clinical judgment of a qualified medical professional. In the event of a suspected obstetric emergency, contact emergency services immediately.